Investor Webinar: Telix Therapeutics Urology Showcase and Expert Forum
March 04, 2025 | 04:58
Telix Pharmaceuticals Limited invites investors to join a webinar showcasing the Company's late-stage and next-generation radiotherapeutic candidates in urologic oncology.
Illuccix Approved in the United Kingdom
February 13, 2025 | 04:30
Telix Pharmaceuticals Limited today announces that the United Kingdom Medicines and Healthcare Products Regulatory Agency has approved the Marketing Authorization Application for its prostate cancer PET imaging agent Illuccix®.
Telix to Acquire Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform
January 13, 2025 | 05:34
Telix Pharmaceuticals Limited today announces it has entered into an asset purchase agreement with antibody engineering company ImaginAb, Inc.
FDA accepts new drug application and grants priority review for TLX101-CDx brain cancer imaging agent
October 24, 2024 | 05:02
Telix Pharmaceuticals Limited today announces that the United States Food and Drug Administration has accepted the new drug application for TLX101-CDx.
Latest News
Mobile Version